JP7739319B2 - Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法 - Google Patents

Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法

Info

Publication number
JP7739319B2
JP7739319B2 JP2022554486A JP2022554486A JP7739319B2 JP 7739319 B2 JP7739319 B2 JP 7739319B2 JP 2022554486 A JP2022554486 A JP 2022554486A JP 2022554486 A JP2022554486 A JP 2022554486A JP 7739319 B2 JP7739319 B2 JP 7739319B2
Authority
JP
Japan
Prior art keywords
cells
vector
cell
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517940A5 (https=
JP2023517940A (ja
Inventor
マタ，メリンダ
カルラ，マムタ
ウォルター，シュテフェン
モハメド，アリ
ブリアード，ヤニック
Original Assignee
イマティクス ユーエス，アイエヌシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマティクス ユーエス，アイエヌシー． filed Critical イマティクス ユーエス，アイエヌシー．
Publication of JP2023517940A publication Critical patent/JP2023517940A/ja
Publication of JP2023517940A5 publication Critical patent/JP2023517940A5/ja
Priority to JP2025145583A priority Critical patent/JP2025182221A/ja
Application granted granted Critical
Publication of JP7739319B2 publication Critical patent/JP7739319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022554486A 2020-03-11 2021-03-10 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法 Active JP7739319B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025145583A JP2025182221A (ja) 2020-03-11 2025-09-02 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988202P 2020-03-11 2020-03-11
US62/988,202 2020-03-11
PCT/US2021/021701 WO2021183643A1 (en) 2020-03-11 2021-03-10 Wpre mutant constructs, compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025145583A Division JP2025182221A (ja) 2020-03-11 2025-09-02 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法

Publications (3)

Publication Number Publication Date
JP2023517940A JP2023517940A (ja) 2023-04-27
JP2023517940A5 JP2023517940A5 (https=) 2024-03-19
JP7739319B2 true JP7739319B2 (ja) 2025-09-16

Family

ID=75278397

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554486A Active JP7739319B2 (ja) 2020-03-11 2021-03-10 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法
JP2025145583A Pending JP2025182221A (ja) 2020-03-11 2025-09-02 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025145583A Pending JP2025182221A (ja) 2020-03-11 2025-09-02 Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法

Country Status (9)

Country Link
US (3) US11851673B2 (https=)
EP (1) EP4118218A1 (https=)
JP (2) JP7739319B2 (https=)
KR (1) KR20230015313A (https=)
CN (1) CN115667535A (https=)
AR (1) AR121546A1 (https=)
DE (1) DE102020111571A1 (https=)
TW (1) TW202200789A (https=)
WO (1) WO2021183643A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
CN113423419A (zh) * 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20230190806A1 (en) * 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of treating metastatic lesions and compositions thereof
GB202204926D0 (en) * 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4662231A1 (en) * 2023-02-10 2025-12-17 Expression Therapeutics, LLC Lentiviral system
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520016A (ja) 2000-10-06 2004-07-08 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
JP2018502583A (ja) 2015-01-12 2018-02-01 ジュノー セラピューティクス インコーポレイテッド 修飾された肝炎転写後調節エレメント
JP2021501589A (ja) 2017-11-06 2021-01-21 イマティクス バイオテクノロジーズ ゲーエムベーハー 新規操作ｔ細胞受容体およびそれを使用した免疫療法
JP2021513355A (ja) 2018-02-14 2021-05-27 ジェネレーション バイオ カンパニー 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用
JP2021534791A (ja) 2018-08-28 2021-12-16 法▲羅▼斯疫苗株式会社 改良されたレンチウイルスベクター
JP2022534716A (ja) 2019-05-27 2022-08-03 イマティクス ユーエス，アイエヌシー． ウイルスベクターおよびその養子細胞療法における使用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (https=) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
EP0854193A1 (en) 1990-09-21 1998-07-22 Chiron Corporation Human retroviral packaging cell line
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE4309553A1 (de) 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
AU3635695A (en) 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5800706A (en) 1996-03-06 1998-09-01 Hyperion Catalysis International, Inc. Nanofiber packed beds having enhanced fluid flow characteristics
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DE69941049D1 (de) 1998-05-22 2009-08-13 Oxford Biomedica Ltd Retrovirales verabreichungssystem
US7262049B2 (en) 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2003277694A1 (en) 2002-11-04 2004-06-07 Cho-A Pharm Co., Ltd. Porcine uroplakin ii promoter and the production method of useful proteins using said promoter
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
CN101180082B (zh) 2005-02-23 2012-02-08 生物载体株式会社 利用siv-pedf载体治疗伴随眼组织细胞凋亡变性的疾患的药物
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
EP2140004B1 (en) 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
EP2019134A1 (en) 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
JP5559185B2 (ja) 2008-11-11 2014-07-23 オックスフォード バイオメディカ（ユーケー）リミテッド 方法
US20100150889A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic Vector For Human Induced Pluripotent Stem Cell Production
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
DE102009021592A1 (de) 2009-05-15 2010-11-18 Medizinische Hochschule Hannover ASLV-Vektorsystem
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
KR101451357B1 (ko) 2011-02-18 2014-10-15 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
EP2694687B1 (en) 2011-04-08 2018-01-31 Anthem Biosciences Pvt Ltd An in vitro method for high throughput screening of genotoxic agents in eukaryotic cells
WO2013158962A1 (en) 2012-04-19 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle
US9982034B2 (en) 2012-10-24 2018-05-29 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
US9943611B2 (en) 2012-11-01 2018-04-17 California Institute Of Technology Reversible gene expression
US8975042B2 (en) 2012-12-21 2015-03-10 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
US9290552B2 (en) 2012-12-21 2016-03-22 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
US9534248B2 (en) 2013-09-10 2017-01-03 The Board Of Trustees Of The Leland Stanford Junior University Tumor-specific minicircles for cancer screening
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20180772A1 (es) 2015-07-01 2018-05-07 Univ California Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10335471B2 (en) 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
CN106658540B (zh) 2015-10-28 2021-07-09 索尼公司 无线通信系统中的装置和方法
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
US9975926B2 (en) 2015-12-08 2018-05-22 The United States of America, as Represented by the Secretary of Homeland Security Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
EP3390432B1 (en) 2015-12-18 2020-09-23 Ucl Business Ltd Treatment
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CN116769054A (zh) * 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
WO2017144080A1 (en) 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
HUE055862T2 (hu) 2016-04-20 2021-12-28 Centro De Investig Energeticas Készítmények és eljárások PKLR fokozott génexpressziójára
US10907930B2 (en) 2016-07-08 2021-02-02 Bryce L. Betteridge Impact absorbing padding system with elastomeric sub-surface structure
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
KR20240151726A (ko) 2016-09-08 2024-10-18 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. 판코니 빈혈 환자를 위한 유전자 치료
AU2017370640A1 (en) 2016-12-05 2019-07-18 The Regents Of The University Of California Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11866699B2 (en) 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
EP4653536A3 (en) 2017-03-17 2026-02-25 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
SG11202000840YA (en) 2017-07-31 2020-02-27 Reflection Biotechnologies Ltd Cellular models of and therapies for ocular diseases
AU2018313167A1 (en) 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
KR102696307B1 (ko) 2017-09-08 2024-08-16 제너레이션 바이오 컴퍼니 비-바이러스성 캡시드-비함유 dna 벡터의 지질 나노입자 제형
CA3075168A1 (en) 2017-09-08 2019-03-14 Generation Bio Co. Modified closed-ended dna (cedna)
KR20250052472A (ko) 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
CA3084185A1 (en) 2017-12-06 2019-06-13 Generation Bio Co. Gene editing using a modified closed-ended dna (cedna)
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
US12442015B2 (en) 2018-01-19 2025-10-14 Generation Bio Co. Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
MA51915A (fr) 2018-02-22 2020-12-30 Generation Bio Co Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019195729A1 (en) 2018-04-05 2019-10-10 Nightstarx Ltd. Aav compositions, methods of making and methods of use
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520016A (ja) 2000-10-06 2004-07-08 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
JP2018502583A (ja) 2015-01-12 2018-02-01 ジュノー セラピューティクス インコーポレイテッド 修飾された肝炎転写後調節エレメント
JP2021501589A (ja) 2017-11-06 2021-01-21 イマティクス バイオテクノロジーズ ゲーエムベーハー 新規操作ｔ細胞受容体およびそれを使用した免疫療法
JP2021513355A (ja) 2018-02-14 2021-05-27 ジェネレーション バイオ カンパニー 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用
JP2021534791A (ja) 2018-08-28 2021-12-16 法▲羅▼斯疫苗株式会社 改良されたレンチウイルスベクター
JP2022534716A (ja) 2019-05-27 2022-08-03 イマティクス ユーエス，アイエヌシー． ウイルスベクターおよびその養子細胞療法における使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gene Ther.，2008年，Vol.15, No.21，p.1411-1423
Gene Therapy，2006年，Vol.13, No.7，p.641-645
Gene Therapy，2009年，Vol.16, No.5，p.605-619

Also Published As

Publication number Publication date
WO2021183643A1 (en) 2021-09-16
JP2025182221A (ja) 2025-12-12
EP4118218A1 (en) 2023-01-18
TW202200789A (zh) 2022-01-01
DE102020111571A1 (de) 2021-09-16
US20240150790A1 (en) 2024-05-09
US11851673B2 (en) 2023-12-26
US20250075230A1 (en) 2025-03-06
US12123013B2 (en) 2024-10-22
AR121546A1 (es) 2022-06-15
KR20230015313A (ko) 2023-01-31
JP2023517940A (ja) 2023-04-27
US20210285011A1 (en) 2021-09-16
CN115667535A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7739319B2 (ja) Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法
JP7536808B2 (ja) 養子細胞療法薬を製造するための改善された方法
US20250333469A1 (en) Use of cd8-targeted viral vectors
ES2877398T3 (es) Vectores retrovíricos y lentivíricos
CN111394317B (zh) 改善的t细胞组合物
JP6538716B2 (ja) Ｍｎｄプロモーターのキメラ抗原受容体
US20240344083A1 (en) Use of cd4-targeted viral vectors
JP2022548509A (ja) ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ
KR20220029584A (ko) 바이러스 벡터 및 입양 세포 요법에서 그 사용
EP4602174A1 (en) Viral particles targeting hematopoietic stem cells
JP2025510948A (ja) Ｃｄ４特異的抗体構築物及び組成物ならびにその使用
US20250152709A1 (en) Cd3-targeted lentiviral vectors and uses thereof
CN118043469A (zh) 靶向cd4的病毒载体的用途
CN117098849A (zh) 靶向cd8的病毒载体的用途
DE102020106710A1 (de) Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2025512407A (ja) Ｃｍｖ－ｈｉｖ特異的キメラ抗原受容体ｔ細胞
WO2025209590A1 (zh) 一种病毒载体包装系统及其应用
EA048022B1 (ru) Вирусные векторы и их применение в адоптивной клеточной терапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250903

R150 Certificate of patent or registration of utility model

Ref document number: 7739319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150